医学
肿瘤科
内科学
CD44细胞
危险系数
比例危险模型
预测标记
西妥昔单抗
头颈部鳞状细胞癌
放化疗
尼妥珠单抗
癌症
无进展生存期
免疫组织化学
头颈部癌
总体生存率
细胞
结直肠癌
表皮生长因子受体
置信区间
生物
遗传学
作者
Usha Patel,Sadhana Kannan,Swapnil Rane,Neha Mittal,Poonam Gera,Asawari Patil,Subhakankha Manna,Vishwayani Shejwal,Vanita Noronha,Amit Joshi,Vijay Patil,Kumar Prabhash,Manoj B. Mahimkar
标识
DOI:10.1038/s41416-022-01730-9
摘要
Anti-EGFR-based therapies have limited success in HNSCC patients. Predictive biomarkers are needed to identify the patients most likely to benefit from these therapies. Here, we present predictive and prognostic associations of different cancer stem cell markers in HPV-negative locally advanced (LA) HNSCC patients.Pretreatment tumour tissues of 404 HPV-negative LA-HNSCCs patients, a subset of-phase 3-randomised study comparing cisplatin-radiation(CRT) and nimotuzumab plus cisplatin-radiation(NCRT) were examined. The expression levels of CD44, CD44v6, CD98hc, ALDH1A1, SOX2 and OCT4A were evaluated using immunohistochemistry. Progression-free survival(PFS), loco-regional control(LRC),- and overall survival(OS) were estimated by Kaplan-Meier method. Hazard ratios were estimated by Cox proportional hazard models.NCRT showed significantly improved OS with low membrane expression of CD44 compared to CRT [HR (95% CI) = 0.63 (0.46-0.88)]. Patients with low CD44v6 also showed better outcomes with NCRT [LRC: HR (95% CI) = 0.25 (0.10-0.62); OS: HR (95% CI) = 0.38 (0.19-0.74)]. No similar benefit with NCRT observed in patients with high CD44 or CD44v6 expression. Bootstrap resampling confirmed the predictive effect of CD44 (Interaction P = 0.015) and CD44v6 (Interaction P = 0.041) for OS. Multivariable Cox analysis revealed an independent negative prognostic role of CD98hc membrane expression for LRC [HR (95% CI) = 0.63(0.39-1.0)] and OS[HR (95% CI) = 0.62 (0.40-0.95)].CD44 and CD44v6 are potential predictive biomarkers for NCRT response. CD98hc emerged as an independent negative prognostic biomarker.Registered with the Clinical Trial Registry of India (Trial registration identifier-CTRI/2014/09/004980).
科研通智能强力驱动
Strongly Powered by AbleSci AI